Last edition
News about Global Pharma
US FDA Grants Priority Review to Sarclisa for Treatment of Transplant-Ineligible NDMM
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab).
Global Pharma | 28/05/2024 | By Aishwarya | 916
This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments.
Global Pharma | 27/05/2024 | By Manvi | 1427
SystImmune Appoints Dr. Jonathan Cheng as New Chief Medical Officer
He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
Global Pharma | 27/05/2024 | By Manvi | 996
Orna Therapeutics Acquires ReNAgade to Strengthen Expertise in RNA Therapies
Orna Therapeutics has recently acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
Global Pharma | 27/05/2024 | By Aishwarya | 347
Merck Signs Definitive Deal to Acquire Mirus Bio for USD 600 Million
Merck has signed a definitive agreement to acquire Mirus Bio for USD 600 million.
Global Pharma | 27/05/2024 | By Aishwarya | 688
Global Group Introduces Innovative Salivary Testing Pilot to Combat Oral Health Disparities
Global Group, Inc., in a strategic alliance with technology partner Oral Genome, announce an innovative program aimed at tackling global oral health disparities.
Global Pharma | 24/05/2024 | By Manvi | 481
YS Biopharma Announces Name Change to LakeShore Biopharma
The name change and trading symbol change will not affect any rights of shareholders or the Company's operations and financial position. The Company's ordinary shares and warrants will continue to be listed on the Nasdaq.
Global Pharma | 24/05/2024 | By Manvi | 555
Biossmann Appoints Pankaj Kedia as Chief AI Officer to Drive Global Expansion and Innovation
Kedia, a renowned technology industry executive and AI thought-leader, joins Biossmann to spearhead its global expansion and drive innovation, positioning the company as a powerhouse in medical solutions.
Global Pharma | 24/05/2024 | By Abha | 1026
Indica Labs and Hamamatsu Photonics Receive FDA Clearance for HALO AP Dx Digital Pathology Platform
HALO AP Dx is indicated for the primary diagnosis of surgical pathology slides prepared from formalin-fixed paraffin-embedded (FFPE) tissue scanned by the NanoZoomer® S360MD Slide scanner.
Global Pharma | 24/05/2024 | By Abha | 657
Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance
Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.
Global Pharma | 23/05/2024 | By Aishwarya | 993
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy